clinical trials

Biofrontera to report Q1 2026 results May 14, advancing Ameluz® commercialization and clinical expansion into skin cancers and acne.

INmune Bio reported Q1 2026 net loss of $5.4M, down from $9.7M year-ago. Company advancing XPro for Alzheimer's with $21.4M cash on hand.

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

Privium Fund Management acquires $5.07M stake in Denali Therapeutics following FDA approval of first commercial drug Avlayah for Hunter syndrome treatment.

Global stem cell therapy market projected to grow from $21.9B in 2025 to $58.5B by 2034 at 11% CAGR, driven by technological advances and favorable regulations.

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.

Pulse Biosciences reported Q1 2025 net losses amid clinical expansion, with $119.3M cash and three devices progressing toward commercialization milestones.

Cryoport reports Q1 2026 revenue of $47.8M, up 16% YoY, raising full-year guidance to $192-196M as CGT revenue surges.

Hepatic encephalopathy market projected to grow 1.2% annually through 2036, reaching $900M in 2025, driven by emerging therapies and increased diagnosis awareness.

Iovance Biotherapeutics surged 34% in 2026 on strong melanoma drug sales, with analysts projecting 165% upside. Manufacturing challenges present significant execution risks.

Oculis will present its ophthalmology pipeline at ARVO 2026, with Phase 3 results for lead DME candidate OCS-01 expected in June.

Complement inhibitors market projected for strong growth through 2036, driven by rising disease prevalence and C5/C3-targeted drug approvals across multiple indications.

Krystal Biotech will present gene therapy data across three major conferences in May-June 2026, highlighting programs targeting ciliary dyskinesia, cystic fibrosis, and immunotherapy.

CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.

PTCL market valued at USD 800 million in 2025 to grow 7% annually through 2036, driven by emerging therapies and rising disease incidence. U.S. represents 68% of market.

Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.

Abbott reports strong clinical trial data for AFib and cardiac devices, with 87% arrhythmia-free rates and 98.3% safety in FlexPulse study, supporting future revenue growth.